PTO/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0331
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Application Number		10/05253			
	Filing Date		2004-02-23			
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Min		Mimoto			
Not for submission under 37 CFR 1.99)	Art Unit		2681			
,	Examiner Name NGU		NGUYEN, TUAN HOANG			
	Attorney Docket Numb	er	CFA00057US			

					U.S.	PATENTS			Remove		
Examiner Initial*	Patent Number	Kind Code <sup>1</sup>	Issue E	Date	Name of Pat of cited Docu	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1	5214410		1993-0	5-25	Verster, Theu	nis C.				
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*						Relev		Lines where ges or Relev			
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap					d butto	Remove		
	_			FOREIG	GN PAT	ENT DOCUM	IENTS			1	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	74
	1	2002-162918	JP		A	2002-06-07	DAINIPPON PRIN CO LTD	TING			
	2	08-161653	JP		A	1996-06-21	NIPPON SYST HO	DUSE			
	3	08-335238	JP		A	1996-12-17	FUJITSU LTD				

#### 

If you wisl	to a	dd add	ditional	Foreign	Pati	tent D	Docum	ment	t cita	tion is	nforr	natio	n pleas	e click t	he Add	buttor	· [	Add	]		
						NO	N-P	ATE	NT L	JTEF	RAT	JRE	DOCU	MENTS			R	emove	9		
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iten (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.										Тs											
	1																				
If you wis	n to a	dd add	ditional	non-pa	tent I	literat	ture c	docu	umen	t cita	tion	inforr	nation	please	lick the	Add b	outto	n A	dd		
								E)	XAM	INER	SIG	NAT	URE								
Examiner	Signa	ture												Date (	Conside	red					
*EXAMIN citation if																				ough a	

1 See Kind Codes of USPTO Patent Documents at year USPTO\_GOD/ or MPEP 901.04. <sup>2</sup> Either office that issued the document, by the ho-ellest code (WIPO Standard ST3.) <sup>2</sup> Eor Jupanese patent countered, by machinion of the year of the Emperor must protect the sear-in unbrute of the Patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>3</sup> Applicant is to place a check mark here if English language transitation is attacked.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10785253					
Filing Date		2004-02-23					
First Named Inventor	Mimo	to					
Art Unit		2681					
Examiner Name	NGU	YEN, TUAN HOANG					
Attorney Docket Numb	er	CFA00057US					

#### CERTIFICATION STATEMENT

Please see 37	CFR :	1.97 ar	d 1.98 to	make the ap	propriate	selection(	s)
---------------	-------	---------	-----------	-------------	-----------	------------	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signifie pic certification after making reasonable inclusir, or send of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(e)(2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Sivon Kalmınov/	Date (YYYY-MM-DD)	2006-08-03
Name/Print	Sivon Kalminov	Registration Number	40042

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. D. 6bb 1450, Alexandria, V.S.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.2231-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.